The Center for Clinical and Translational Science proudly presents…

COVID-19 Inventor Showcase

The CCTS’s Optimizing Innovation, Commercialization and Entrepreneurship of Biomedical Research program is launching a monthly panel series to highlight experts who are working together to fight against COVID-19 on our front lines of innovation.

Tuesday, July 14 | Noon – 1 p.m | Webinar
Enhancing Innate COVID-19 Immunity

After 500,000 deaths, WHO warns that the worst of the coronavirus pandemic is “yet to come.” While most COVID-19 patients have mild or moderate courses, up to 10% can have severe, potentially life-threatening complications. These circumstances have led to an urgency to create effective treatments and therapies. Join us to learn how researchers at Nationwide Children’s Hospital developed a method for generating large numbers of clinical-grade Natural Killer (NK) cells for cancer therapy which has the potential to augment the innate immunity of high-risk patients with mild or moderate COVID-19 disease and to prevent progression to severe COVID-19 disease.

LEARN MORE  REGISTER NOW

Inventor Team
Christopher P. Ouellette, MD
Nationwide Children’s Hospital Division of Infectious Diseases

Dean Lee, MD, PhD
Nationwide Children’s Hospital Division of Hematology & Oncology

Centers & Institutes Teams
Kevin Bosse, PhD, RAC
Nationwide Children’s Hospital Drug and Device Development Services

Christopher P. Ouellette, MD
Nationwide Children’s Hospital Host Defense Program

Margaret Lamb, MD
Nationwide Children’s Hospital Cellular Therapy and Cancer Immunology Program

Dean Lee, MD, PhD
OSU/NCH Campus GMP Facilities for Cell Therapy Manufacturing

Co-presented by:
Ohio State’s Corporate Engagement Office
Nationwide Children’s Hospital Office of Technology Commercialization